SAS Output

20-AUG-2018 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 220 54 23 5 1 0 09/19/2014 227 100
            220 54 23 5 1 0      
 
    2 Y 2 Continuous Dosing 237 94 27 12 5 2 0 09/19/2014    
        3 Intermittent Dosing   90 24 12 4 1 0      
            184 51 24 9 3 0      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 13 10 7 3 1 0 02/06/2017 90 42
            13 10 7 3 1 0      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 2 2 2 2 0 0 06/05/2018 30 19
            2 2 2 2 0 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 8 8 6 5 1 1 10/23/2017 235 94
        2 Nivolumab + Ipilimumab   14 14 9 7 2 2      
            22 22 15 12 3 3      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   27 10 3 1 1 1 11/03/2015 365 156
            27 10 3 1 1 1      
 
    2 E Total Registrations   10 6 5 3 3 0 11/03/2015    
            10 6 5 3 3 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 306 121
            36 0 0 0 0 0